SCHEMBL6891847

SCHEMBL6891847

Cn1ccc(-c2cnn3c(N)cc(C4CCC5C(=O)NC(=O)N5C4)nc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.46
CCNA2 P20248 13/20 0.46
CDK2 P24941 13/20 0.46
CCNA1 P78396 13/20 0.46
KDM4E B2RXH2 4/20 0.36
MEN1 O00255 4/20 0.36
NPC1 O15118 4/20 0.36
MAPT P10636 4/20 0.36
RAB9A P51151 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
GFER P55789 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7882256 0.88 CHEK1 (0.59) CHEK1CCNA2CDK2CCNA1
SCHEMBL6894425 0.83 CHEK1 (0.50) CHEK1CCNA2CDK2CCNA1
SCHEMBL6891869 0.82 CHEK1 (0.43) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL6893499 0.81 CHEK1 (0.46) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL7874728 0.81 CHEK1 (0.46) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL6894418 0.79 NPC1 (0.36) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL14516619 0.78 CHEK1 (0.50) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL6894127 0.78 CHEK1 (0.44) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL6891866 0.78 CHEK1 (0.51) CHEK1CCNA2CDK2CCNA1KDM4E
SCHEMBL10234237 0.76 CHEK1 (0.49) CHEK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 CHEK1 2755/4885CCNA2 2265/4885CDK2 457/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.